pharmaphorum5d
A history of: Mapping breast cancer’s journey from past to present
As the decade progressed, other novel targeted agents, including lapatinib and bevacizumab were developed to disrupt additional growth signalling pathways in certain breast cancer subtypes.
Medscape3d
FDA OKs Adjuvant Ribociclib in Earlier Stage Breast Cancer
The US Food and Drug Administration (FDA) approved ribociclib (Kisqali, Novartis) in combination with an aromatase inhibitor for adult patients with hormone receptor (HR)-positive, human epidermal ...
The American Journal of Managed Care5d
FDA Approves Ribociclib for Early Breast Cancer Treatment With High Recurrence Rate
The FDA approved ribociclib (Kisqali) for adjuvant treatment of high-risk, hormone receptor-positive, HER2-negative early breast cancer. The FDA approved ribociclib (Kisqali) with an aromatase ...
MedPage Today5d
FDA Expands Approval of Ribociclib to Early Breast Cancer
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA on Tuesday approved ribociclib (Kisqali) in combination with endocrine therapy as adjuvant treatment for early ...
Cancer Research3d
STING Immune Pathway Discovery Earns Lasker Prize
Zhijian ‘James’ Chen, PhD, has been awarded the Albert Lasker Basic Medical Research Award for his 2012 discovery of how the cGAS-STING pathway senses cytosolic DNA to trigger immune responses. This ...
Indiatimes2d
Kisqali wins FDA nod for breast cancer treatment: Dosage, effectiveness and side effects of the breakthrough drug
The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It targets high-risk HR-positive, HER2-negative stage II and III patients ...
Relay Therapeutics: 2nd-Line RLY-2608 Data Moves Program Towards Expansion
Relay Therapeutics was able to report positive interim data from its phase 1 study, using RLY-2608 + fulvestrant. Learn more ...
Yahoo Finance5d
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Basel, September 17, 2024 – Novartis today announced that the US Food and Drug Administration (FDA) has approved Kisqali ® (ribociclib) in combination with an aromatase inhibitor (AI ...
STAT4d
FDA awards Novartis expanded approval for breast cancer therapy
Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But on Tuesday, the Food and Drug Administration approved ...
oncnursingnews5d
FDA Approves Adjuvant Ribociclib Plus AI Therapy for HR+, HER2- Breast Cancer
The Food and Drug Administration approved ribociclib plus an aromatase inhibitor for hormone receptor (HR)–positive, HER2-negative stage II and III early breast cancer that has a high risk of ...
Targeted Oncology6d
Dual HER2 Blockade Plus Ribociclib Offers Chemo-Free Option in HR+/HER2+ Breast Cancer
Combining endocrine therapy with the dual HER2 blockade of trastuzumab and pertuzumab and the CDK4/6 inhibitor ribociclib showed potential as a novel approach for patients with HR+/HER2+ breast cancer ...